JP2821211B2 - Prophylactic and therapeutic agent for Klebsiella pneumoniae infection - Google Patents

Description

The present invention relates to a prophylactic and therapeutic agent for Klebsiella pneumoniae infection. Specifically, it is a prophylactic and therapeutic agent for Klebsiella pneumoniae infection containing a specific crude drug as an active ingredient.

[Prior art] Klebsiella pneumoniae was first isolated from Fried
Friedlander's bacillus (also known as Friedlander's bacillus) was isolated from the lungs of pneumonia patients by a lander.
us). Klebsiella pneumoniae is a facultatively anaerobic, nonmotile, gram-negative bacillus without spores and flagella that has a shape close to an ellipse with blunt circles at both ends and is entirely wrapped in a capsule.
Klebsiella pneumoniae is found in the respiratory tract and feces of normal humans, and is the causative agent of human pneumonia (lobular pneumonia, bronchial pneumonia, etc.), urinary tract infections, and infant diarrhea. Although pneumonia caused by the fungus is not common, its mortality rate is high. K. pneumoniae subs as subspecies
p. pneumoniae, pneumoniae, subsp.ozaenae, subsp.
There is rhinoscleromatis, which has recently been regarded as one of the causative bacteria of opportunistic infections, and may secondary to pulmonary blood disease and purulent diseases of various organs or local organs.

In the treatment of Klebsiella pneumoniae infection, antibiotics such as streptomycin and sulfa drugs such as sulfadiazine are usually used. However, treatment with chemotherapeutic agents such as sulfa drugs and antibiotics has a drawback that resistant bacteria appear. In addition, when chemotherapeutic agents such as antibiotics are administered over a long period of time to treat diseases and malignant tumors caused by bacteria other than Klebsiella pneumoniae, opportunistic infections occur, Klebsiella pneumoniae grows and colonizes, and especially on the host side. If the resistance is low, it causes Klebsiella pneumoniae infection and exacerbates the symptoms.

[Details of the Invention] The present inventors have continued research on a method for preventing and treating Klebsiella pneumoniae infection that is safe and easy with high preventive and therapeutic effects. As a result, of the many herbal medicines, Kayoko and Shiso are extremely effective in preventing and treating Klebsiella pneumoniae infection, and when using these herbal medicines, the drawbacks of the above-mentioned conventional methods due to chemotherapeutic agents Did not occur, and completed the present invention.

Therefore, the present invention is a prophylactic and therapeutic agent for Klebsiella pneumoniae infection, comprising as an active ingredient at least one crude drug selected from Kayoko and Shiso.

Kayoko and Shiso are well-known crude drugs, but it has never been known that these crude drugs are effective in the prevention and treatment of Klebsiella pneumoniae infection, and was first discovered by the present inventors. Things.

Briefly describing the above crude drugs used in the present invention, Cassiae Semen is a one-year grass of Indian origin, Cassia obtussifolia L.
The seeds are rhomboid up to 5 mm in length and glossy, containing emodin, and used as laxatives and visual acuity enhancers.

Moreover, perillae frutescens is perilla leaves and seeds, and contains sisoaldehyde (perillylaldehyde), limonene, pinene, anthocyan dye and the like as components and is used as a sedative, an antitussive and the like.

The prophylactic and therapeutic agents of the present invention include humans; animals such as pigs, cows, horses, goats, noodles, rabbits, dogs, cats, monkeys, and rats; poultry and other birds; prevention of Klebsiella pneumoniae infections in fish and the like. And therapeutic agents.

When the crude drug of the present invention is used for prevention of Klebsiella pneumoniae infection, infection of the human, animal, etc. to which the crude drug has been administered can be prevented, and even if the infection takes place, the symptoms are slightly died. In many cases. In addition, when the crude drug of the present invention is used for treatment of humans or animals infected with Klebsiella pneumoniae infection, healing or symptoms are reduced.

The prophylactic and therapeutic agent of the present invention is obtained by cutting, coarsely pulverizing, or pulverizing a crude drug substance or a crude drug (crude drug substance, cutting, coarsely pulverizing or powdering) with a solvent such as water. The active ingredient contained therein may be extracted by an extraction treatment. When used in the form of an extract,
The extract as it is, the extract is made into a concentrate or a diluent, and is made into a paste, or the extract is powdered, granulated,
It can be used in solid form such as tablets, coated tablets, capsules, pills and the like.

Use in the form of an extract is desirable because the active ingredient can be easily and efficiently taken. The extraction of the active ingredient from Kayoko and Shiso can be carried out by any of the methods and apparatuses commonly used for extracting active ingredients from crude drugs, especially from Kayoko and Shiso. For example, the active ingredient can be extracted into a liquid by immersing or decocting the raw material, coarsely crushed material or powder of Kayoko and Shiso in water or another solvent, and the liquid temperature and extraction time during the extraction process. The conditions such as the type of crude drug, the form of crude drug, the type and amount of liquid for extraction, the stability of extracted components, and the presence or absence of volatility of the extracted components may be appropriately selected. Normal,
Using about 1 to 1000 ml of liquid for extraction per 1 g of dried crude drug substance, coarsely ground product or powder, at a temperature of about 4 to 100 ° C,
It should be performed for about 1 minute to 10 days. The extraction treatment may be performed in any state of standing, stirring, and shaking. As the liquid for extraction, in addition to water, organic solvents such as methanol, ethanol, butanol, acetone, ethyl acetate, ether, methylene chloride, chloroform, benzene, carbon tetrachloride, and petroleum ether can be used. Water, methanol, ethanol or mixtures thereof, especially water, are preferred.

In addition, when the active ingredient is further concentrated and recovered as an extract from the active ingredient-containing extract prepared as described above, a method of partially or completely removing the solvent of the extract by heating or other methods, the active ingredient And any other method, such as a method of separating and separating the active ingredient with a precipitant, a method of adding another extraction solvent to the active ingredient-containing extract, transferring the active ingredient to the other solvent, and then concentrating the active ingredient. it can. When the solvent used for the extraction and concentration of the active ingredient is one whose use is pharmaceutically prohibited, the agent is sufficiently purified so that the prophylactic and therapeutic agent of the present invention does not finally contain the solvent. It is necessary.

When administering the prophylactic and therapeutic agents of the present invention,
Both oral and parenteral administration can be employed. In the case of oral administration, the agent of the present invention is directly supplied to humans or animals or the like, or is added to foods, feeds, drinking water and the like, and then supplied. In the case of parenteral administration, any of intramuscular administration by injection or application, intraperitoneal administration, transdermal administration, nasal administration, intravenous administration, etc. can be adopted. For parenteral administration, it is convenient to use it in liquid form.

The dosage is determined by the type of crude drug, the form at the time of administration of the crude drug (for example, a crude drug substance or an active ingredient extract, etc.), the type and age of the administration target, and the dosage form (oral administration or parenteral administration). Depending on the condition or physical condition of the human or animal to be administered, etc., in the case of oral administration, it is usually 0.001 to 10 g / body weight k in terms of a dried crude drug substance or a crushed product or powder thereof.
g / day in a range of several days to several tens of days.
In the case of parenteral administration, it is usually administered in the range of 0.01 mg to 1 g / kg / day of body weight over several days to several tens of days in terms of a dry crude drug substance or a crushed product or powder thereof. Is preferred.

Hereinafter, the present invention will be described specifically with reference to examples, but the present invention is not limited to these examples.

Example 1 A dried powder was put into distilled water so as to have a concentration of 5% w / v, and slowly heated at a temperature of 100 ° C. for 30 minutes to prepare an extract. After filtering this extract, dilute it 5 times with water,
This solution alone was placed in a water bottle and 14 mice (C3H / HeN
(6 weeks old) for 2 weeks.

Then Klebsiella pneumoniae ATCC 1388
3) was intraperitoneally administered at a rate of 10 ⁷ / animal to infect the mice, and then the above five-fold diluted Kaneko extract was freely taken for one week.

In this case, the survival rate one week after administration of K. pneumoniae was 9 (survival rate: 64%).

Example 2 Extraction and dilution were carried out in the same manner as in Example 1 above, except that dried soybean leaf was used instead of dried soybean powder, to prepare a 5-fold diluted extract of soybean leaves. This was used for 7 mice (C3H /
HeN (6 weeks old) was fed in the same manner as in Example 1, and then infected with Klebsiella pneumoniae in the same manner as in Example 1.
One week after administration of Klebsiella pneumoniae, the number of surviving animals was 4 (survival rate: 57%).

Comparative Example Sixteen mice (C3H / HeN♀6 weeks old) were allowed to freely ingest water as in Examples 1 and 2 by placing only water in a water bottle. When Klebsiella pneumoniae was administered to the intraperitoneal cavity and infected in the same manner as in Examples 1 and 2, the number of surviving one week after administration of Klebsiella pneumoniae was 1 (survival rate: 6%).

From the results of the above Examples 1 and 2 and Comparative Example, it is understood that the agent of the present invention containing the extract of Kayoko or Shiso is effective for the prevention and treatment of Klebsiella pneumoniae infection.

[Effects of the Invention] In the present invention, at least one of Akiko and Shiso is used as a prophylactic and therapeutic agent for Klebsiella pneumoniae infection,
The prevention and treatment of Klebsiella pneumoniae infection can be performed simply and extremely effectively.

Since the prophylactic and therapeutic agent for Klebsiella pneumoniae infection of the present invention is a crude drug, its safety is higher than that of conventionally used chemotherapeutic agents such as antibiotics and synthetic chemicals, and emergence of resistant bacteria,
Less likely to cause problems such as opportunistic infections.

──────────────────────────────────────────────────続 き Continued on the front page (58) Field surveyed (Int.Cl. ⁶ , DB name) A61K 35/78

Claims (1)

(57) [Claims] An agent for preventing and treating Klebsiella pneumoniae, comprising as an active ingredient at least one crude drug selected from Kayoko and Shiso.